Genitourinary Cancer

4:43
Erdafitinib for FGFR-mutated urothelial carcinoma
Arlene Siefker-Radtke
2:35
Urothelial carcinoma treatment: the future
Arlene Siefker-Radtke
1:09
Enfortumab vedotin: targeting bladder cancer
Arlene Siefker-Radtke
2:18
EMA restrict pembrolizumab/atezolizumab usage in urothelial cancer
Thomas Powles
3:34
ABACUS trial: preoperative atezolizumab in urothelial carcinoma
Thomas Powles
3:07
Vinflunine shows a chemotherapeutic advantage for locally-advanced and metastatic penile cancer
Lisa Pickering
2:38
The current treatment landscape for penile cancer
Lisa Pickering
1:29
Could cabozantinib be a successful novel therapy for mCRPC?
Gregory Pond
2:54
A 6-factor prognostic model for urothelial carcinoma patients receiving atezolizumab
Gregory Pond
3:45
Updates on immunotherapy options for metastatic urothelial carcinoma
Kirollos Hanna
3:50
Recommendations for the treatment of muscle and non-muscle invasive urothelial carcinoma
Kirollos Hanna
2:12
Looking towards the future: what is in store for the treatment of bladder cancer?
Kirollos Hanna
1:49
HOPA 2018 updates on urothelial carcinoma: what is new?
Kirollos Hanna
2:06
A golden age for bladder cancer publications
Andrea Apolo
0:44
Unmet needs in bladder cancer in the immunotherapy era
Andrea Apolo
1:14
How can we continue the success of checkpoint inhibitors for bladder cancer treatment?
Andrea Apolo
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJOncology is intended for healthcare professionals